Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG04 Belimumab
D03068 Belimumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
B lymphocyte Stimulator-specific Inhibitor
Belimumab
D03068 Belimumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03068 Belimumab (USAN); Belimumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNFSF13B (BAFF, CD257)
D03068 Belimumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03068
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03068
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03068
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03068
